72 related articles for article (PubMed ID: 10550570)
1. Wortmannin inhibits the growth of mammary tumors despite the existence of a novel wortmannin-insensitive phosphatidylinositol-3-kinase.
Lemke LE; Paine-Murrieta GD; Taylor CW; Powis G
Cancer Chemother Pharmacol; 1999; 44(6):491-7. PubMed ID: 10550570
[TBL] [Abstract][Full Text] [Related]
2. In vitro and in vivo antitumor activity of the phosphatidylinositol-3-kinase inhibitor, wortmannin.
Schultz RM; Merriman RL; Andis SL; Bonjouklian R; Grindey GB; Rutherford PG; Gallegos A; Massey K; Powis G
Anticancer Res; 1995; 15(4):1135-9. PubMed ID: 7653991
[TBL] [Abstract][Full Text] [Related]
3. Wortmannin, a phosphoinositide 3-kinase inhibitor, selectively enhances cytotoxicity of receptor-directed-toxin chimeras in vitro and in vivo.
Davol PA; Bizuneh A; Frackelton AR
Anticancer Res; 1999; 19(3A):1705-13. PubMed ID: 10470104
[TBL] [Abstract][Full Text] [Related]
4. Advances with phospholipid signalling as a target for anticancer drug development.
Powis G; Berggren M; Gallegos A; Frew T; Hill S; Kozikowski A; Bonjouklian R; Zalkow L; Abraham R; Ashendel C
Acta Biochim Pol; 1995; 42(4):395-403. PubMed ID: 8852330
[TBL] [Abstract][Full Text] [Related]
5. Studies on the mechanism of phosphatidylinositol 3-kinase inhibition by wortmannin and related analogs.
Norman BH; Shih C; Toth JE; Ray JE; Dodge JA; Johnson DW; Rutherford PG; Schultz RM; Worzalla JF; Vlahos CJ
J Med Chem; 1996 Mar; 39(5):1106-11. PubMed ID: 8676346
[TBL] [Abstract][Full Text] [Related]
6. The phosphatidylinositol 3-kinase inhibitor wortmannin sensitizes murine fibroblasts and human tumor cells to radiation and blocks induction of p53 following DNA damage.
Price BD; Youmell MB
Cancer Res; 1996 Jan; 56(2):246-50. PubMed ID: 8542574
[TBL] [Abstract][Full Text] [Related]
7. Wortmannin inhibits growth of human non-small-cell lung cancer in vitro and in vivo.
Boehle AS; Kurdow R; Boenicke L; Schniewind B; Faendrich F; Dohrmann P; Kalthoff H
Langenbecks Arch Surg; 2002 Oct; 387(5-6):234-9. PubMed ID: 12410360
[TBL] [Abstract][Full Text] [Related]
8. Phosphatidylinositol 3-kinase recruitment by p185erbB-2 and erbB-3 is potently induced by neu differentiation factor/heregulin during mitogenesis and is constitutively elevated in growth factor-independent breast carcinoma cells with c-erbB-2 gene amplification.
Ram TG; Ethier SP
Cell Growth Differ; 1996 May; 7(5):551-61. PubMed ID: 8732665
[TBL] [Abstract][Full Text] [Related]
9. Heregulin-beta is especially potent in activating phosphatidylinositol 3-kinase in nontransformed human mammary epithelial cells.
Ram TG; Hosick HL; Ethier SP
J Cell Physiol; 2000 Jun; 183(3):301-13. PubMed ID: 10797304
[TBL] [Abstract][Full Text] [Related]
10. Phosphatidylinositol 3-kinase activity is not essential for CD28 costimulatory activity in Jurkat T cells: studies with a selective inhibitor, wortmannin.
Lu Y; Phillips CA; Trevillyan JM
Eur J Immunol; 1995 Feb; 25(2):533-7. PubMed ID: 7875216
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of mTOR activity restores tamoxifen response in breast cancer cells with aberrant Akt Activity.
deGraffenried LA; Friedrichs WE; Russell DH; Donzis EJ; Middleton AK; Silva JM; Roth RA; Hidalgo M
Clin Cancer Res; 2004 Dec; 10(23):8059-67. PubMed ID: 15585641
[TBL] [Abstract][Full Text] [Related]
12. Novel quinone antiproliferative inhibitors of phosphatidylinositol-3-kinase.
Frew T; Powis G; Berggren M; Gallegos A; Abraham RT; Ashendel CL; Zalkow LH; Hudson C; Gruszecka-Kowalik E; Burgess EM
Anticancer Drug Des; 1995 Jun; 10(4):347-59. PubMed ID: 7786399
[TBL] [Abstract][Full Text] [Related]
13. A wortmannin-sensitive phosphatidylinositol 4-kinase that regulates hormone-sensitive pools of inositolphospholipids.
Nakanishi S; Catt KJ; Balla T
Proc Natl Acad Sci U S A; 1995 Jun; 92(12):5317-21. PubMed ID: 7777504
[TBL] [Abstract][Full Text] [Related]
14. Molecular pharmacology and antitumor activity of PX-866, a novel inhibitor of phosphoinositide-3-kinase signaling.
Ihle NT; Williams R; Chow S; Chew W; Berggren MI; Paine-Murrieta G; Minion DJ; Halter RJ; Wipf P; Abraham R; Kirkpatrick L; Powis G
Mol Cancer Ther; 2004 Jul; 3(7):763-72. PubMed ID: 15252137
[TBL] [Abstract][Full Text] [Related]
15. Growth-inhibitory effect of phosphatidylinositol 3-kinase inhibitor on human pancreatic cancer cells and expression of Bcl-2 family.
Katayose K; Seki T; Ohba N; Funatomi H; Goto N; Mitamura K
Anticancer Res; 2003; 23(3B):2383-7. PubMed ID: 12894518
[TBL] [Abstract][Full Text] [Related]
16. Interleukin-12 inhibits angiogenesis and growth of transplanted but not in situ mouse mammary tumor virus-induced mammary carcinomas.
Lee JC; Kim DC; Gee MS; Saunders HM; Sehgal CM; Feldman MD; Ross SR; Lee WM
Cancer Res; 2002 Feb; 62(3):747-55. PubMed ID: 11830529
[TBL] [Abstract][Full Text] [Related]
17. Estrogen receptor beta growth-inhibitory effects are repressed through activation of MAPK and PI3K signalling in mammary epithelial and breast cancer cells.
Cotrim CZ; Fabris V; Doria ML; Lindberg K; Gustafsson JÅ; Amado F; Lanari C; Helguero LA
Oncogene; 2013 May; 32(19):2390-402. PubMed ID: 22751110
[TBL] [Abstract][Full Text] [Related]
18. Overexpression and hyperactivity of breast cancer-associated fatty acid synthase (oncogenic antigen-519) is insensitive to normal arachidonic fatty acid-induced suppression in lipogenic tissues but it is selectively inhibited by tumoricidal alpha-linolenic and gamma-linolenic fatty acids: a novel mechanism by which dietary fat can alter mammary tumorigenesis.
Menendez JA; Ropero S; Mehmi I; Atlas E; Colomer R; Lupu R
Int J Oncol; 2004 Jun; 24(6):1369-83. PubMed ID: 15138577
[TBL] [Abstract][Full Text] [Related]
19. Tyrosine kinase inhibitor emodin suppresses growth of HER-2/neu-overexpressing breast cancer cells in athymic mice and sensitizes these cells to the inhibitory effect of paclitaxel.
Zhang L; Lau YK; Xia W; Hortobagyi GN; Hung MC
Clin Cancer Res; 1999 Feb; 5(2):343-53. PubMed ID: 10037184
[TBL] [Abstract][Full Text] [Related]
20. In vitro metabolism of the phosphatidylinositol 3-kinase inhibitor, wortmannin, by carbonyl reductase.
Holleran JL; Fourcade J; Egorin MJ; Eiseman JL; Parise RA; Musser SM; White KD; Covey JM; Forrest GL; Pan SS
Drug Metab Dispos; 2004 May; 32(5):490-6. PubMed ID: 15100170
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
